Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes
Cells · 2024
DOI: 10.3390/cells13100828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Shinichi Matsumoto und 1 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Transplantation, Heterologous. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan IDDM network.
Abstract (Originalsprache)
Allogeneic islet transplantation has become a standard therapy for unstable type 1 diabetes. However, considering the large number of type 1 diabetic patients, the shortage of donors is a serious issue. To address this issue, clinical islet xenotransplantation is conducted. The first clinical islet xenotransplantation was performed by a Swedish team using fetal pancreatic tissue. Thereafter, clinical trials of islet xenotransplantation were conducted in New Zealand, Russia, Mexico, Argentina, and China using neonatal pig islets. In clinical trials, fetal or neonatal pancreata are used because of the established reliable islet isolation methods. These trials demonstrate the method’s safety and efficacy. Currently, the limited number of source animal facilities is a problem in terms of promoting islet xenotransplantation. This limitation is due to the high cost of source animal facilities and the uncertain future of xenotransplantation. In the United States, the first xenogeneic heart transplantation has been performed, which could promote xenotransplantation. In Japan, to enhance xenotransplantation, the ‘Medical Porcine Development Association’ has been established. We hope that xenogeneic transplantation will become a clinical reality, serving to address the shortage of donors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
- Medical Porcine Development Organization, Kobe 650-0017, Japan.
- Second Department of Surgery, Wakayama Medical University, Wakayama 641-0012, Japan.
ORCID-Profile: Shinichi Matsumoto
Förderung
- Japan IDDM network
Zitieren
APA
Matsumoto, S., & Matsumoto, K. (2024). Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes. Cells. https://doi.org/10.3390/cells13100828
Vancouver
Matsumoto S, Matsumoto K. Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes. Cells. 2024. doi:10.3390/cells13100828
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Shinichi and Matsumoto, Kyohei},
title = {Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13100828}
}
EUVIMED